BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• 

  Timothy Bonis

  Timothy Bonis is an AB candidate at Dartmouth College and a former student intern at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.
• 

  S. Sean Tu

  S. Sean Tu is a professor at West Virginia University College of Law and a nationally recognized expert on patent law and drug law.
  
  
  
  
• 

  Career Advice

  Stoicism in the Workplace: Old Philosophies in a New Light

  Gratitude, a key part of stoicism, can benefit those working in—and being served by—the pharmaceutical industry.

  December 18, 2024

   · 

  4 min read

   · 

  Jill Marie Drury
• 

  Podcast

  Biopharma’s Manufacturing Push and Other 2024 Trends

  The Novo-Catalent deal now moving ahead highlights unprecedented investment in manufacturing, while also standing out as an exception to the unspoken rule of keeping M&As to less than $5 billion this year.

  December 18, 2024

   · 

  1 min read

   · 

  Jef Akst
• 

  GLP-1

  FDA Issues Warning Letters Against Online GLP-1 Sellers

  The letters come amid the Outsourcing Facilities Association’s ongoing lawsuit against the FDA over the regulator’s decision to end the shortage for tirzepatide.

  December 18, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  GLP-1

  Merck Joins Obesity Pill Race With Up to $2B Hansoh Deal

  The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk and Roche.

  December 18, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Novo Adds Novel Approach to Cardiometabolic Pipeline With Photys Collab

  Photys is eligible for up to $186 million from Novo Nordisk for its PHICS small molecules that pair a kinase to a disease-causing protein for phosphorylation.

  December 18, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• 

  Cardiovascular disease

  Tenaya Stock Crashes as Cardio Gene Therapy Delivers Underwhelming Early-Stage Data

  Tenaya’s share slump following the TN-201 data drop could be due to its “significantly lower” level of RNA expression in the Phase Ib/II trial than in preclinical models, according to William Blair analysts.

  December 18, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  Biopharma’s Big Question of 2024: Can You Scale It?

  Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of pharma is going to be vying for capacity and talent.

  December 18, 2024

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  Opinion

  Lessons From Humira on How to Tackle Unjust Extensions of Drug Monopolies With Policy

  AbbVie’s blockbuster Humira held 105 patents, shielding the anti-inflammatory drug from biosimilar competition for more than 20 years. Proposed reforms could help prevent companies from extending exclusivity with such patent thickets.

  December 18, 2024

   · 

  4 min read

   · 

  Timothy Bonis